Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

Polycystic Ovarian Syndrome Clinical Trial

— NIMO  

Official title:

Using Nimodipine, a Calcium Channel Blocker, to Prevent LH Surge in Women Undergoing Controlled Ovarian Stimulation and Intrauterine Insemination: a Double-blinded, Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01672801
• Other study ID #: 2012P-000186
• Status: Completed
• Phase: N/A
• Start date: September 2012
• Est. completion date: April 2014

Study information

• Verified date: August 2020
• Source: Boston IVF
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to test the effectiveness of nimodipine in preventing a luteinizing hormone (LH) surge in women undergoing ovulation induction with clomiphene citrate. It is important to prevent the premature LH surge in controlled ovarian stimulation to allow adequate recruitment of follicles, proper maturation of a dominant follicle before ovulation, and effectively time insemination with semen to allow fertilization of a mature egg to occur.

The investigators are also conducting this study to determine medication side effect profile (including lightheadedness or dizziness from low blood pressure or rapid heart rate, headache, and nausea), patient treatment compliance, and clinical pregnancy (positive pregnancy test and ultrasound evidence of fetal heart rate). Finally, LH and follicle stimulating hormone (FSH) serum levels will be measured to determine effect of nimodipine on these hormones.

As a calcium channel blocker, nimodipine has been shown to block calcium mediated release of gonadotropin releasing hormone in animal and preliminary human studies. The investigators hypothesize that nimodipine, a calcium channel blocker, will prevent or delay the LH surge during controlled ovarian stimulation cycles using clomiphene citrate in subfertile patients undergoing assisted reproduction with intrauterine insemination (IUI).

Description:

After enrollment, subjects will be randomized to Placebo Comparator or Active Comparator. All subjects will receive Clomid 100 mg for 5 days for the purpose of ovarian follicle recruitment. Intervention will be initiated once ovarian follicle maturation has been documented (≥1 ovarian follicle size of ≥ 17mm) and the absence of a premature LH surge has been confirmed - this will be classified as intervention day 0. Subjects will receive their assigned comparator (Placebo or Active) according the schedule below:

• Intervention Day 0 - noon / afternoon / bedtime (3 doses)

• Intervention Day 1 - morning / noon / afternoon / bedtime (4 doses)

• Intervention Day 2 - morning (1 dose) Serum hormone levels and ultrasound examination will occur on days 0,1 and 2 for all subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 25 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age 25-40 years at the time of enrollment

• Both ovaries intact by history and ultrasound assessment

• Early follicular phase (day 2-4) serum FSH level <20 mIU/mL

• Diagnosis of subfertility with a recommended treatment of COH and IUI

• Providing written informed consent in English

Exclusion Criteria:

• Body mass index (BMI) >38 kg/m2

• Early follicular phase (day 2-4) serum FSH level =20 mIU/mL

• History of overstimulated cycle defined as >3 mature follicles of =17 mm

• Abnormal uterine cavity and/or tubal disease (as evidenced by sonohysterogram or hysterosalpingogram)

• Diagnosis of infertility with a clear indication for in-vitro fertilization, such as bilateral tubal occlusion

• Severe male factor infertility: Total Motile Sperm Count < 2x106 post washing (sperm deemed inadequate for IUI preparation)

• Any ovarian or abdominal abnormality that may interfere with adequate TV ultrasound evaluation

• Absence of one or both ovaries

• Any contraindication to being pregnant or carrying a pregnancy to term

• Unexplained gynecological bleeding

• Any medical condition that would jeopardize the patient or the integrity of the data obtained including:

• Prior reaction or side effects from previous calcium channel blocker use

• Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of nimodipine such as hepatic disease, hypertension, seizure, concurrent infection, depression, reflux (see #12 below).

• Mental health status resulting in cognitive or emotional impairment that would preclude study participation

• The concurrent use of any of the following drugs: [These medications have been shown to effect the availability of the medication or worsen hypotension symptoms]

• Antihypertensives (eg. ACE inhibitors, alpha-adrenergic blocking agents,methyldopa, beta-blockers, diuretics, PDE5 inhibitors, and other calcium antagonists)

• Antiepileptics (eg. phenobarbital, phenytoin, carbamazepine or valproic acid)

• Macrolide antibiotics (eg, erythromycin)

• Azole antimycotics (eg, ketoconazole)

• HIV protease inhibitors (eg, ritonavir)

• Antidepressants (eg, nefazodone and fluoxetine)

• Cimetidine

• Patient unable to communicate adequately with the investigators and to comply with the requirements of the study

• Unwillingness to give written informed consent

Related Conditions & MeSH terms

• Anovulatory
• Infertility
• Polycystic Ovarian Syndrome
• Polycystic Ovary Syndrome
• Unexplained Infertility

Intervention

Drug:
• Placebo
oral administration
• Nimodipine
oral administration

Locations

Country	Name	City	State
United States	Boston IVF	Waltham	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Boston IVF	Village Fertility Pharmacy

Country where clinical trial is conducted

United States, 

References & Publications (3)

Chen EC, Javors MA, Norris C, Siler-Khodr T, Schenken RS, King TS. Dependence of 3',5'-cyclic adenosine monophosphate--stimulated gonadotropin-releasing hormone release on intracellular calcium levels and L-type calcium channels in superfused GT1-7 neurons. J Soc Gynecol Investig. 2004 Sep;11(6):393-8. — View Citation

Krsmanovic LZ, Stojilkovic SS, Merelli F, Dufour SM, Virmani MA, Catt KJ. Calcium signaling and episodic secretion of gonadotropin-releasing hormone in hypothalamic neurons. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8462-6. — View Citation

Núñez L, Villalobos C, Boockfor FR, Frawley LS. The relationship between pulsatile secretion and calcium dynamics in single, living gonadotropin-releasing hormone neurons. Endocrinology. 2000 Jun;141(6):2012-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Gonadotropin Levels	Calculated changes in serum LH, FSH, and estradiol levels between patients in nimodipine and placebo arms	Intervention day 0 to ovulation (approximately 1-7 days)
Primary	LH Surge	Compare the change between placebo treated and nimodipine treated patients by the presence or absence of an LH surge on intervention Day 1 and Day 2. LH surge will be determined by serum LH levels at least two times the baseline serum LH (baseline serum LH = (cycle day 3 serum [LH] + cycle day 7 serum [LH])/2).	7 days
Secondary	Number of Participants Experiencing Side Effects	Medication side effect profile including: symptomatic hypotension (Note: vital signs will be recorded), symptomatic tachycardia (Note: vital signs will be recorded), headache, nausea. These will be self-reported with constructed questionnaire.	Starting day 0 of intervention to pregnancy test (approximately 15 days)